We’re thrilled to announce our partnership with Illumina on this groundbreaking licensable dataset. Click the link below to learn more.
Roughly one in eight adults in the United States have used a glucagon-like peptide-1 (GLP-1) receptor agonist, but studies show that almost 40% do not respond effectively to treatment. We're launching a dataset to enable better understanding the molecular basis of GLP-1 therapy responses. In collaboration with Ovation, we're creating the first real-world, multiomic GLP-1 dataset based on samples from 25,000 patients treated with GLP-1 therapies. This tool will be available to pharma partners to support acceleration of therapy development, research of expanded use indications, and discovery of novel biomarkers and drug targets in nonresponsive populations. For more on our collaboration with Ovation: https://bit.ly/42RLTSQ